Complementary Insulin-Based Approaches for Achieving HA1c Targets in Patients with T2D


- ARS-Based, Interactive Session Focused on Patient with T2D Who is on Metformin and SGLT-2 Inhibitor plus a Basal Insulin and Still Has Suboptimal Control of Total HA1c Level in Combination with Evidence of PPG.


 - ARS-Based, Interactive Session Focused on a Patient with T2D Who Has a High Risk for Hypoglycemia, is Overweight, and Despite Basal Insulin Therapy Plus Metformin and an SGLT-2 Inhibitor, and has Significantly Elevated Post-Prandial Glucose Levels.


ARS-Based, Interactive Session Focused on Patient with T2D Who is Not Meeting HA1c Targets, is Averse to Multiple Daily Injections, is at Risk for Hypoglycemia, and Would Benefit from Weight Loss and a Simplified Regimen for Glycemic Control

Program Medium

Internet-based program


Estimated Time to Complete Educational Activity

2.5 hours


Course Overview

In this web-based program, physicians and optometrists will learn how recent developments have helped to advance the management of Type 2 diabetes


Release Date

May 15, 2018


Expiration Date

May 15, 2020


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period May 15, 2018  through May 15, 2020 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 9 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.



articipation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.


Grantor Support

Supported by an educational grant from Sanofi Diabetes


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMEducation Resources. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation Statement

The Postgraduate Institute for Medicine designates live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Policy on Faculty & Provider Disclosure

It is the policy of Postgraduate Institute for Medicine to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by Postgraduate Institute for Medicine are required to present evidence-?based data, identify and reference off-?label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.


Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.


Program Faculty and Disclosure

Juan P. Frias, MD
Program Chair 
Endocrinology, Diabetes and Metabolism 
Clinical Assistant Professor of Medicine 
University of California, San Diego 
President and Principal Investigator 
National Research Institute
Contracted Research: AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, BMS, Elcelyx, Eli Lilly, Genentec,  IONIS, Janssen, Johnson & Johnson, Lexicon, Ligand, Madrigal, Merck, Mylan, Myovant, Novartis, Novo Nordisk, Ogeda, Pfizer, Sanofi, TaiwanJ, Theracos, Viking  Sanofi, Merck
Speaker: Sanofi, Merck 
Consultant: AstraZeneca, BMS, Echosens, Elcelyx, Johnson & Johnson, Ligand, Novo Nordisk, Sanofi

Pablo F. Mora,  MD, FACE, CDE
Dallas Diabetes Research Center at Medical City Dallas (Texas)
Adjunct Associate Professor
University of Texas Southwestern Medical Center at Dallas (Texas)
Consultant and Speaker’s Bureau: Novo Nordisk
Speaker’s Bureau: Sanofi US

Neil SkolnikK, M.D.
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Sanofi
Speaker: AstraZeneca, Boehringer Ingelheim
Consultant: AstraZeneca, Teva, Lilly, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim, Sanofi, Intarcia


Educational Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients who, because of postprandial hyperglycemia, are not optimizing overall HA1c target goal attainment; and who, therefore, may be appropriate candidates for therapy with specific agents, including GLP-?1 agonists, in combination with basal insulin, to optimize their glycemic management;
  • Utilize pharmacotherapy-?based approaches to metabolic optimization — pan-?glycemic control, weight loss, etc. — in patients with T2D, with a focus on insulin-?based formulations;
  • Titrate the dose(s) of both basal insulin and a GLP-?1 agonist, when used in fixed-?ratio combination formulations, to achieve optimal HA1c control, weight loss, reduction in risk of hypoglycemia, and postprandial glucose control — i.e. to achieve metabolic state optimization in patients with T2D;
  • Recognize when a physiologic, long-?acting basal insulin is appropriate to reduce risk of hypoglycemia in appropriate patients;
  • Implement complementary, multi-?mechanistic approaches to diabetes care, with a focus on optimizing the safety-?efficacy equation for glycemic control and comprehensive metabolic management by employing a fixed ratio, basal insulin plus GLP-?1 RA combination formulation;


Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.


Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.